Omid Hamid, MD

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, discusses current and emerging immunotherapeutic strategies in the field of melanoma during an interview at the 34th Annual Chemotherapy Foundation Symposium^TM.

Hamid says the future will hold adding more tolerable regimens in to the treatment paradigm of melanoma, based on the past success of the treatments already utilized and approved.

Omid Hamid, MD, discusses sequencing and combining targeted therapies in the treatment of melanoma.

Omid Hamid, MD, discusses promising combination therapies for the treatment of melanoma.

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses treatment decisions for patients with melanoma.